anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a targeted long-circulating urokinase nanoparticle and a preparation method thereof. The raw materials comprise urokinase, carrier material, surfactant and target polypeptide. The preparation method adopts an improved multiple emulsion solvent volatilization method for preparation. The structure uses carrier material as matrix, surface modification targeting polypeptide and coating urokinase. The long-circulating nanoparticle has low toxicity and long in-vivo residence time, and can be effectively prevented from being cleared by reticuloendothelial systems. In addition, the preparation method is feasible and reliable in operation, and the obtained carrier has the advantages of higher drug loading rate, better thrombus targeting property, excellent slow release effect, longer in-vivo half-life, remarkable thrombolysis effect, high suspension stability, good biocompatibility and the like.
BACKGROUND: Pulmonary arterial hypertension (PAH) ultimately leads to right ventricular failure and premature death. The identification of circulating biomarkers with prognostic utility is considered a priority. As chronic inflammation is recognized as key pathogenic driver, we sought to identify inflammation-related circulating proteins that add incremental value to current risk stratification models for long-term survival in patients with PAH.
METHODS AND RESULTS: Plasma levels of 384 inflammatory proteins were measured with the proximity extension assay technology in patients with PAH (n=60) and controls with normal hemodynamics (n=28). Among these, 51 analytes were significantly overexpressed in the plasma of patients with PAH compared with controls. Cox proportional hazard analyses and C-statistics were performed to assess the prognostic value and the incremental prognostic value of differentially expressed proteins. A panel of 6 proteins (CRIM1 [cysteine rich transmembrane bone morphogenetic protein regulator 1], HGF [hepatocyte growth factor], FSTL3 [follistatin-like 3], PLAUR [plasminogen activator, urokinase receptor], CLSTN2 [calsyntenin 2], SPON1 [spondin 1]) were independently associated with death/lung transplantation at the time of PAH diagnosis after adjustment for the 2015 European Society of Cardiology/European Respiratory Society guidelines, the REVEAL (Registry to Evaluate Early and Long-Term PAH Disease Management) 2.0 risk scores, and the refined 4-strata risk assessment. CRIM1, PLAUR, FSTL3, and SPON1 showed incremental prognostic value on top of the predictive models. As determined by Western blot, FSTL3 and SPON1 were significantly upregulated in the right ventricle of patients with PAH and animal models (monocrotaline-injected and pulmonary artery banding-subjected rats).
CONCLUSIONS: In addition to revealing new actors likely involved in cardiopulmonary remodeling in PAH, our screening identified promising circulating biomarkers to improve risk prediction in PAH, which should be externally confirmed.
Intractable nausea can occur in numerous settings. We report on a 49-year-old woman with a past medical history of cystic fibrosis (CF) with chronic hypoxia, chronic nausea, complex infection history and frequent hospitalizations who was admitted to an academic medical center with a CF exacerbation. Her chronic nausea worsened with the use of antimicrobials, and she was unable to tolerate dopamine or serotonin antagonist antiemetics. Nausea persisted despite the use of benzodiazepines and antihistamines. She was given a one-time dose of fosaprepitant 150 mg intravenously (IV) with marked improvement of her nausea. During subsequent exacerbations, she again developed severe nausea which continued to respond well to a one-time dose of fosaprepitant 150 mg IV. Fosaprepitant is a substance P/neurokinin-1 (NK1) receptor antagonist that is FDA-approved for the prevention of chemotherapy-induced nausea and vomiting and has been used to prevent post-operative nausea and vomiting. Its use in other contexts has not been well established. This case suggests a role for fosaprepitant in the management of nausea outside the context of chemotherapy or general anesthesia.
To evaluate the safety and efficacy of the Chinese domestic endoscopic instrument control system in clinical treatment.This clinical trial is a prospective, multi-center, randomized, single-blind, parallel-controlled study. The system used in the experimental group is the endoscopic instrument control system developed by WEGO Surgical Robot Co., Ltd., and the system used in the control group is the da Vinci endoscopic instrument control system developed by Intuitive Surgical. Before patients are enrolled in this clinical study, the researchers will do a detailed screening of the subjects based on the inclusion criteria and the exclusion criteria to determine if the patients are appropriate for the clinical study. Patients who meet the conditions of the study will be required to sign an informed consent form. Then they will be randomly assigned to the experimental group or the control group. To evaluate the primary outcome measures and secondary outcome measures and to observe the incidence of organ and vascular injury. Finally, we evaluate the safety and efficacy of the test product through the comparison of the data obtained from the experimental group and the control group during the treatment.
A cosmetic cleansing agent containing a first biosurfactant in combination with a second, anionic surfactant have a prebiotic effect on the skin. The prebiotic effect pertains to the promotion of growth of skin-friendly microorganisms, such as Staphylococcus epidermidis and S. warneri, and the concurrent inhibition of growth of pathogenic bacteria, such as Propionibacterium acnes. The cleansing agent may contain 1-20% wt, preferably 1-10% wt, of a biosurfactant and 1-10% wt, preferably 3-10% wt, of an anionic surfactant. The biosurfactant may be a glycolipid preferably selected from rhamnolipids, sophorolipids or mannosylerythritol lipids a lipopeptide preferably selected from surfactins, fatty acyl glutamates or fatty acyl glycinates or a combination thereof. The anionic surfactant may be a linear alkyl sulfate or an ethylene oxide addition product thereof, such as lauryl ether (2-4 EO) sulfate. The cleansing agent preferably contains no free fatty acids and only a small amount of preservative which does not disrupt the skins microflora balance, e.g. 0.2-0.7% wt. It may be formulated as a body or face cleansing agent and is suitable for treating acne. The use of biosurfactants, alone or combined with anionic surfactants, in cosmetic cleansing agents to provide a prebiotic effect on the skin is also claimed.
PURPOSE:A cyclodextrin clathrate substance, obtained by coexistence of cyclodextrin or derivative thereof and surfactant in a process for extracting a crude drug or herb medicine and capable of preventing loss of active ingredients of the crude drug or herb medicine. CONSTITUTION:A clathrate substance containing active ingredients of a crude drug or herb medicine included in cyclodextrin or a derivative thereof. Although an essence derived from an extract or powder, granule or tablet prepared by drying the extract has been used as a substitute for a decoction of the crude drug or herb medicine, the composition components are different between the decoction and the extract. The coexistence of the cyclodextrin, e.g. alpha- cyclodextrin, and a surfactant, e.g. alkyl or alkenyl sulfate having 10-20C alkyl or alkenyl, in an extraction process eliminates loss of the active ingredients of the crude drug or herb medicine and drug efficacy similar to that of the decoction can be expected.
OBJECTIVES: Few studies have been conducted on gene-environment interactions in the Chinese population with Crohn's disease (CD). We aimed to investigate the association between single nucleotide polymorphisms (SNPs) on the T helper 17 (Th17) cell and CD susceptibility/performance in Chinese individuals.
METHODS: We conducted a case-control and case-only study at the Peking Union Medical College Hospital. Four SNPs related to the Th17 cell pathway genes were prioritized, including rs2284553 (interferon gamma receptor 2), rs7517847 (interleukin 23 receptor), rs7773324 (interferon regulatory factor 4), and rs4263839 (tumor necrosis factor superfamily 15). SNP frequency was calculated, and gene-environment interaction was assessed by multifactor dimensionality reduction analysis.
RESULTS: Altogether 159 CD patients and 316 healthy controls were included. All analyzed SNPs were found in Hardy-Weinberg equilibrium (P > 0.05). The frequency of rs2284553-A allele and rs4263839-A allele were lower in CD patients compared with controls (P < 0.05). While the rs4263839-A allele was more prevalent in ileocolonic CD patients than in those with isolated small intestinal or colonic disease (P = 0.035). Gene-environment interactions revealed associations between rs2284553 and breastfeeding, sunshine exposure, and fridge-stored food, affecting age at diagnosis, intestinal involvement, and intestinal stricture. Interaction of rs4263839 and breastfeeding influenced small intestinal lesions and intestinal stricture in CD.
CONCLUSIONS: This study provided information on the genetic background in Chinese CD patients. Incorporating these SNPs into predictive models may improve risk assessment and outcome prediction. Gene-environment interaction contributes to the understanding of CD pathogenesis.
PROBLEM TO BE SOLVED: To obtain a dentin-adhesive composition comprising a specific compound, a radically polymerizable monomer and a polymerization initiator and having excellent adhesivity to dentin such as enamel. SOLUTION: This dentin-adhesive composition comprises a compound of formula I (R is H, methylene; X is a 1-6C alkylene, a 1-6C alkylene ether; Y is a 3-5C alkylene), a radically polymerizable monomer and a polymerization initiator. The compound of formula I is e.g. N-(meth)acryloyloxymethyl-ε- caprolactam of formula II (R is H, methyl). The concentration of the compound of formula I is 0.1-50wt.%, especially 0.5-20wt.%. The radically polymerizable monomer includes methyl (meth)acrylate and ethylene glycol di(meth)acrylate. The polymerization initiator is e.g. perbenzoyl peroxide-dimethylaniline. The radically polymerizable monomer, the compound of formula I and the polymerization initiator are compounded in amounts of 100 pts.wt., 0.1-50 pts.wt. and 0.1-15 pts.wt., respectively.
This study is an open-label, Phase 1b, dose-escalation/finding study to assess safety and efficacy of intravenous BSG005 in patients with uncomplicated invasive fungal infections (IFI).

The study will be conducted in 3 cohorts consisting of 3 periods, namely: Screening, Treatment, and Follow-up periods. In each cohort, 5 patients are planned to be enrolled. Following 7 days of Screening period, patients will be enrolled in the study. In Cohort 1, patients will be administered with a dose of 0.1 mg/kg, which was tested in the single ascending dose (SAD) group of the Phase 1 healthy subject study and will follow an intra-patient dose-escalation step. Based on the overall health status of the patient (safety and efficacy of study intervention), the dose can be adjusted at any point of time according to the Investigator´s judgment, which would be based on clinical or mycological or radiological assessments dependent on the information available. This can be dose escalation or dose de-escalation as appropriate. During the Treatment period, there may be a pause of one day or more if deemed necessary by the Investigator. Each patient will be evaluated individually for efficacy and safety to decide if escalation is possible. The dose will be escalated by 0.1 mg/kg every 3 days or 1 day earlier (ie, 2 days) at the Investigator's discretion.

The starting dose in Cohort 1 will be 0.1 mg/kg for the first 3 days of treatment; if no safety concerns are experienced, the patients will be escalated up to 0.2 mg/kg. This process will be followed up to a maximum of 1.0 mg/kg or till a maximum of 28 days of treatment duration in Cohort 1, with the possibility to stop anytime after 14 days depending on the status of the patient. The starting dose of Cohort 2 will be decided by the Data Safety Review Committee (DSRC) after review of all available relevant data up to Day 14 of treatment for all patients in Cohort 1. Subsequently, a similar dose-escalation will be followed for Cohort 2 as defined above for Cohort 1. The dose can be escalated up to a maximum of 2.0 kg/mg. A similar process will be followed for the first dose in Cohort 3 and the dose can be escalated up to a maximum of 3.0 mg/kg. BSG005 will be administered daily via IV infusion for 120 minutes (may be prolonged for up to 240 minutes). As BSG005 has a propensity for phlebitis, central catheters or long peripheral catheters are preferred for infusion.
Amphotericin B should be administered intravenously under close clinical observation by medically trained personnel. It should be reserved for treatment of patients with progressive, potentially life-threatening fungal infections due to susceptible organisms (see INDICATIONS AND USAGE).

Acute reactions including fever, shaking chills, hypotension, anorexia, nausea, vomiting, headache, and tachypnea are common 1 to 3 hours after starting an intravenous infusion. These reactions are usually more severe with the first few doses of amphotericin B and usually diminish with subsequent doses.

Rapid intravenous infusion has been associated with hypotension, hypokalemia, arrhythmias, and shock and should, therefore, be avoided (see DOSAGE AND ADMINISTRATION).

Amphotericin B should be used with care in patients with reduced renal function; frequent monitoring of renal function is recommended (see PRECAUTIONS: Laboratory Tests and ADVERSE REACTIONS). In some patients hydration and sodium repletion prior to amphotericin B administration may reduce the risk of developing nephrotoxicity. Supplemental alkali medication may decrease renal tubular acidosis complications.

Since acute pulmonary reactions have been reported in patients given amphotericin B during or shortly after leukocyte transfusions, it is advisable to temporarily separate these infusions as far as possible and to monitor pulmonary function (see PRECAUTIONS: Drug Interactions).

Leukoencephalopathy has been reported following use of amphotericin B. Literature reports have suggested that total body irradiation may be a predisposition.

Whenever medication is interrupted for a period longer than 7 days, therapy should be resumed by starting with the lowest dosage level, e.g., 0.25 mg/kg of body weight, and increased gradually as outlined under DOSAGE AND ADMINISTRATION.
"Double scale" is a poorly characterized skin defect of crocodilians that drastically reduces the economic value of crocodilian skin. This study investigated the morphology and pathogenesis of double scale in a ranching farm of American alligators (Alligator mississippiensis). We compared the histopathology of skin and selected organs (liver, lung, kidney, heart, spleen, intestine, and brain) of alligators with double scale against healthy control animals, together with serum and liver vitamin and mineral levels. Skin affected with double scale had statistically significant hyperkeratosis, epidermal atrophy, and increased basal cell degeneration compared with control alligators (P < .0001). Interestingly, all alligators with double scale had varying degrees of hepatic fibrosis. Feed analysis showed that alligators that had double scale and hepatic fibrosis had prolonged dietary exposure to high levels of vitamin A, iron, and copper. Serum analysis indicated that levels of zinc (p < .0001), copper (P < .05), and vitamin E (P < .002) were significantly lower in alligators with hepatic fibrosis and double scale compared with controls. Finally, immunohistochemical analysis of skin with double scale showed a marked reduction in immunolabeling with the zinc-binding protein metallothionein. These results suggest that zinc deficiency, in combination with other micronutrient anomalies, may play a role in the pathogenesis of double scale in alligators with liver fibrosis.
Capsules (such as hard gelatin, cellulose and plastic capsules) containing pharmaceutical powders which are administered to a patient via inhalation are treated so as to increase the effective amount of the pharmaceutical agent reaching the respiratory system of the patient. The capsules are coated internally with a lubricant during manufacture and in one aspect, the method involves exposing the lubricant-coated inner surface of the capsule to a pharmaceutically acceptable solvent which dissolves the lubricant. Generally, the solvent is volatile, and bactericidal (e.g. ethanol). The pharmaceutical powder is inserted in the capsule following this washing procedure.  Alternatively, the lubricant-coated capsule is dusted internally with a dusting agent such as a salt (e.g. sodium chloride) or a sugar (e.g. lactose, mannitol, trehalose or sucrose) prior to inserting the pharmaceutical powder inside the capsule. The invention also pertains to a capsule, optionally containing the pharmaceutical powder therein, which has been treated according to the methods discussed above.
INTRODUCTION AND HYPOTHESIS: Patient-reported outcomes are relevant outcomes in studies on pelvic organ prolapse (POP) surgery, as anatomical recurrence alone does not have a significant correlation with perceived improvement. In the present study, the patient's impression of improvement after 1 year is studied after vaginal hysterectomy (VH) versus sacrospinous hysteropexy (SSH) in large cohorts from daily clinical practice. We hypothesize that there is no difference between the groups.
METHODS: This is a secondary analysis on prospectively collected data in a multicenter cohort of patients who underwent VH or SSH for symptomatic POP. All patients had a POP-Q stage ≥ 2 in at least one compartment at baseline and were treated with VH or SSH between 2002 and 2019. The primary outcome was the patient-reported score on the patient global impression of improvement index (PGI-I) 1 year after surgery. The secondary outcome was a composite outcome of surgical success, defined as the absence of recurrent POP beyond the hymen with bothersome bulge symptoms and/or repeat surgery.
RESULTS: A total of 378 women (196 VH and 182 SSH) were included. The median score on the PGI-I did not differ between VH and SSH. At 1 year post-operatively, 77 women after VH (73%) and 77 women after SSH (75%) considered their condition (very) much improved (p = 0.86). There was no difference in composite outcome of surgical success (126 out of 137 women [92%] after VH, 118 out of 125 women [94%] after SSH; p = 0.44).
CONCLUSIONS: Our study shows that there was no difference in the type of surgery, VH or SSH, with regard to the patient's impression of improvement 1 year postoperatively in a large cohort from daily clinical practice.
PCT No. PCT/US95/12615 Sec. 371 Date Oct. 6, 1997 Sec. 102(e) Date Oct. 6, 1997 PCT Filed Oct. 11, 1995 PCT Pub. No. WO96/11211 PCT Pub. Date Apr. 18, 1996A method to inhibit translation of an mRNA, which is intitiated at an internal ribosome entry site of the mRNA and requires binding of a protein factor to that site, is disclosed. The method comprises a step of providing, in an in vitro, or in vivo system that is capable of translating the mNRA, an inhibitory effective amount of a molecule that selectively binds to the protein factor, thereby preventing that factor from binding to the mNRA. The inhibitor molecule is an RNA oligonucleotide consisting of less than 35 nucleotides or a structural mimic of such an RNA oligonucleotide. Nucleotide sequences of such inhibitor RNA oligonucleotides include portions of the following sequences: the 60 nucleotide sequence of a yeast inhibitor RNA or of the sequence complementary to that yeast inhibitor RNA; nucleotides 186-220 of poliovirus (stem-loop D); nucleotides 578-618 of poliovirus (stem-loop G); nucleotides 260-415 of poliovirus (stem-loop E); nucleotides 448-556 of poliovirus (stemp-loop F); and the sequence of the internal ribosome entry site of the immunoglobulin heavy chain binding protein (Bip).
PURPOSE: To compare the surgical results of vitrectomy with untreated or pretreated lyophilized human amniotic membrane grafts covering in treating retinal detachment related to posterior retinal breaks above chorioretinal atrophy in pathologic myopia.
METHODS: Nineteen patients with retinal detachment related to macular hole (MH) located above macular atrophy and/or posterior paravascular retinal breaks (PRBs) located above patchy chorioretinal atrophy in pathologic myopia were included. The eyes of these patients underwent vitrectomy with untreated lyophilized human amniotic membrane covering (n = 10) or perfluorocarbon liquid (PFCL)-assisted pretreated lyophilized human amniotic membrane covering (n = 9; grafts were pretreated in 0.125% indocyanine green and 50% hypertonic glucose solution for 15-20 minutes). The closure of the MH or PRBs, reattachment of the retina, and best-corrected visual acuity were measured postoperatively.
RESULTS: Postoperatively, graft dislocation or shift was only found in two eyes (20%) in the untreated group. The closure rate of the MH or PRBs was 80% (8/10) and 100% (9/9) in the untreated group and the pretreated group, respectively. The occurrence rate of excessive gliosis was 40% and 11% in the untreated group and the pretreated group, respectively. In both groups, best-corrected visual acuity was improved and the retinal reattachment rate was 100% at the final visit.
CONCLUSION: Perfluorocarbon liquid-assisted pretreated lyophilized human amniotic membrane graft covering was effective in treating retinal detachment related to MH and/or PRBs situated above macular atrophy or patchy chorioretinal atrophy in pathologic myopia. This technique appeared to reduce graft dislocation or shift, promote the closures of MHs/PRBs, and reduce the occurrence of gliosis.